Internal Medicine, Hematology & Oncology · Yorktown Heights, NY
NPI
1225142656
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
2649 Strang Blvd, Suite 208
Yorktown Heights, NY, 10598
Phone (914) 245-6000
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.8M
249,045 services
Medicare patients, 2024
519
Average age 75
Drug cost, 2024
$4.6M
1,657 prescriptions
Company payments, 2025
$464
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jeffrey Ambinder was code J0881 (injection, darbepoetin alfa, 1 microgram (non-esrd use)), 67,038 times for 42 patients. In total Jeffrey Ambinder billed 249,045 services in 186 codes, and Medicare paid $2.8M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-10-02.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 67,038 | 42 | $2.31 | $155K |
| J1756 Injection, iron sucrose, 1 mg | Office | 42,000 | 47 | $0.18 | $7,400 |
| J0897 Injection, denosumab, 1 mg | Office | 9,061 | 39 | $20.58 | $186K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 6,905 | 34 | $0.09 | $622 |
| 85025 Blood Count | Office | 2,273 | 479 | $7.57 | $17K |
| 82784 Immunoassay | Office | 2,004 | 360 | $9.09 | $18K |
| 80053 Clinical Chemistry | Office | 1,990 | 450 | $10.33 | $21K |
| 84550 Clinical Chemistry | Office | 1,980 | 453 | $4.42 | $8,754 |
| 84100 Clinical Chemistry | Office | 1,966 | 450 | $4.64 | $9,124 |
| 83615 Clinical Chemistry | Office | 1,939 | 449 | $5.91 | $11K |
| 83735 Clinical Chemistry | Office | 1,922 | 449 | $6.56 | $13K |
| 88185 Surgical Pathology Examination | Office | 1,538 | 66 | $22.45 | $35K |
| 82728 Clinical Chemistry | Office | 1,523 | 446 | $13.34 | $20K |
| 99214 Office E&M - Established | Office | 1,392 | 436 | $107.38 | $149K |
| 82746 Clinical Chemistry | Office | 1,345 | 442 | $14.37 | $19K |
By year: 2022 $2.7M for 268,621 services; 2023 $2.3M for 266,076 services; 2024 $2.8M for 249,045 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,273 | 479 | $7.57 | $17K |
| 82784 Immunoassay | 2,004 | 360 | $9.09 | $18K |
| 80053 Clinical Chemistry | 1,990 | 450 | $10.33 | $21K |
| 84550 Clinical Chemistry | 1,980 | 453 | $4.42 | $8,754 |
| 84100 Clinical Chemistry | 1,966 | 450 | $4.64 | $9,124 |
| 83615 Clinical Chemistry | 1,939 | 449 | $5.91 | $11K |
| 83735 Clinical Chemistry | 1,922 | 449 | $6.56 | $13K |
| 88185 Surgical Pathology Examination | 1,538 | 66 | $22.45 | $35K |
| 82728 Clinical Chemistry | 1,523 | 446 | $13.34 | $20K |
| 82746 Clinical Chemistry | 1,345 | 442 | $14.37 | $19K |
Medicare prescription drug claims, 2024
In 2024, the drug Jeffrey Ambinder prescribed most often to Medicare patients was Eliquis (Apixaban), with 149 prescriptions and refills. In total Jeffrey Ambinder wrote 1,657 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 149 | 256 | 36 | $149K |
| Aranesp Darbepoetin Alfa In Polysorbat | 125 | 125 | 40 | $467K |
| Xarelto Rivaroxaban | 72 | 146 | 21 | $78K |
| Levothyroxine Sodium Generic | 59 | 106 | 17 | $851 |
| Anastrozole Generic | 48 | 108 | 15 | $1,114 |
| Folic Acid Generic | 44 | 126 | 16 | $1,127 |
| Akynzeo Fosnetupitant/Palonosetron | 41 | 41 | 12 | $38K |
| Allopurinol Generic | 40 | 90 | 14 | $401 |
| Xgeva Denosumab | 39 | 45 | 14 | $123K |
| Prednisone Generic | 38 | 62 | 13 | $335 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 31 | 59 | Under 11 | $161 |
| Warfarin Sodium Generic | 31 | 88 | Under 11 | $90 |
| Brukinsa Zanubrutinib | 29 | 29 | Under 11 | $315K |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 29 | 29 | Under 11 | $380K |
| Neulasta Onpro Pegfilgrastim | 28 | 28 | Under 11 | $173K |
Brand drugs: 798 claims; generic drugs: 859 claims; opioid claims: 60.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jeffrey Ambinder $464 ($464 in general payments such as food, travel and fees) from 9 companies. The largest payer was Gilead Sciences, Inc. with $140.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.